No licensed Shigella vaccine is presently available globally. A double-blinded, randomized, placebo-controlled, age descending phase II clinical trial of a bivalent conjugate vaccine was studied in China. The vaccine ZF0901 consisted of O-specific polysaccharides purified and detoxified from lipopolysaccharide (LPS) of S. flexneri 2a and S. sonnei and covalently bonded to tetanus toxoid. A total of 224, 310, and 434 children, consented by parents or guardians, aged 3 to 6 and 6 to 12 months and 1 to 5 years old, respectively, were injected with half or full doses, with or without adjuvant or control Hib vaccine. There were no serious adverse reactions in all recipients of ZF0901 vaccine independent of age, dosage, number of injections, or the adjuvant status. Thirty days after the last injection, ZF0901 induced robust immune responses with significantly higher levels of type-specific serum antibodies (geometric mean concentrations (GMCs) of IgG anti-LPS) against both serotypes in all age groups compared with the pre-immune or the Hib control (p < 0.0001). Here, we demonstrated that ZF0901 bivalent Shigella conjugate vaccine is safe and immunogenic in infants and young children and is likely suitable for routine immunization.

Objectives: This randomized, double-blind, active-controlled non-inferiority phase 4 clinical trial was conducted to evaluate the immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine (PPSV23) compared to an active comparator vaccine. Methods: Pneumococcal vaccine-naïve participants aged ≥2 years were randomly assigned in a 2:1 ratio to receive a single dose of either the investigational vaccine (n = 1199) or the comparator vaccine (n = 600). Immunogenicity was evaluated at baseline and 30 days post-vaccination by measuring serotype-specific IgG antibodies against all 23 pneumococcal serotypes using enzyme-linked immunosorbent assay. The primary outcome was seroconversion, defined as a ≥two-fold increase in serotype-specific IgG antibody titers at day 30 compared to baseline. Results: At one month post-vaccination, seroconversion rates for each of the 23 serotypes ranged from 59.22% to 95.67% in the treatment group, compared to 59.66% to 94.07% in the control group. Non-inferiority was demonstrated for all serotypes, with the lower bounds of the 95% confidence intervals (95%CI) for rate differences exceeding the predefined −10% margin. Moreover, superiority was observed for 12 serotypes (6B, 23F, 1, 2, 4, 8, 9N, 9V, 11A, 15B, 17F and 18C), as the lower bounds of their 95%CI for rate differences were above 0. Adverse reactions were reported in 236 (19.68%) participants of the investigational group and 118 (19.67%) of the control group within 30 days post-vaccination, with no significant differences between groups. Conclusions: The PPSV23 vaccine administered among individual aged ≥2 years was safe, well tolerated and immunogenic, eliciting an immune response either comparable to or higher than control vaccine. These findings support its use as a safe and effective option for pneumococcal immunization.

Background/Objectives: The immunogenicity of Streptococcus pneumoniae vaccines is commonly evaluated by assessing the fold increase or proportions exceeding 0.35 μg/mL in serotype-specific IgG antibody levels post-vaccination. Establishing baseline antibody levels in unvaccinated populations is therefore essential for defining serological thresholds and understanding naturally acquired immunity. This study aimed to assess the seroprevalence and baseline levels of IgG antibodies specific to 13 pneumococcal capsular polysaccharide serotypes in healthy infants and young children across multiple regions of China from 2016 to 2023, supporting evidence-based PCV13 vaccination strategies. Methods: IgG concentrations for 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were measured in unvaccinated individuals using the WHO-recommended ELISA. Univariate and multivariate analyses were applied to evaluate regional, age, and gender effects on baseline antibody levels. Results: GMCs for serotypes 6B, 14, 19A, and 19F exceeded 0.35 μg/mL, with 14 being the highest (1.64 μg/mL) and serotypes 3 and 4 the lowest. Significant regional variation (p < 0.001) and a U-shaped age trend were observed, with the lowest being at 7–11 months (p = 0.003). Conclusions: Baseline IgG levels varied by region and age. No significant gender differences were observed, and overall antibody levels were higher in the southern region.

Objectives: A randomized, double-blind, active-controlled noninferiority phase 4 clinical trial was conducted to evaluate the immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine (PPV23). Methods: Pneumococcal vaccine-naïve participants aged ≥2 years were randomly assigned in a 2:1 ratio to receive a single dose of either the treatment vaccine (n=1199) or a comparator vaccine (n=600). We evaluated the immunogenicity before and 30 days post-vaccination, by measuring serum IgG serotype-specific pneumococcal antibodies to 23 serotypes contained in the vaccines via an enzyme-linked immunosorbent assay. The primary outcome was seroconversion (two-fold increase) of serum IgG serotype-specific antibodies at days 30 compared with baseline. Results: One month after the administration of PPV23, seroconversion rates for each of the 23 serotypes ranged from 59.22% to 95.67% in the treatment group, and in the control group from 59.66% to 94.07%. The lower bound of the 95% confidence interval (95%CI) of the rate differences for the 23 serotypes were all larger than −10%. Moreover, 12 serotypes (6B, 23F, 1, 2, 4, 8, 9N, 9V, 11A, 15B, 17F and 18C) had a lower bound of 95%CI for rate difference larger than 0. In total, 236 (19.68%) participants in the treatment group and 118 (19.67%) in the control group reported adverse reactions within 30 days poste-vaccination. No significant differences in incidence of adverse reactions were found between the two comparison groups. Conclusions: The PPV23 vaccine administered among individual aged ≥2 years was safe, well tolerated and immunogenic, eliciting immune response either comparable to or higher than control vaccine.